Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
NL0015436031
Fri, 11.11.2022
CureVac
CureVac Presents Preliminary Data from Phase 1 Study Expansionof Oncology Candidate CV8102
Data confirm CV8102’s safety and ability to strongly mobilize the immune system against tumors
Final data of complete Phase 1 dose-escalation and expansion study expected in H1 2023
TÜBINGEN, Germany/ Boston, USA – November 11, 2022 - CureVac N.V. (Nasda [ … ]
Thu, 10.11.2022
CureVac
CureVac to Report Third Quarter and First Nine Months 2022 Financial Results and Business Updates on November 16, 2022
TÜBINGEN, Germany/ BOSTON, USA – November 10, 2022 – CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), will report financia [ … ]
Thu, 10.11.2022
CureVac
CureVac to Report Third Quarter and First Nine Months 2022 Financial Results and Business Updates on November 16, 2022
TÜBINGEN, Germany/ BOSTON, USA – November 10, 2022 – CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), will report financia [ … ]
Thu, 18.08.2022
CureVac
CureVac Announces Financial Results for the Second Quarter and First Half of 2022 and Provides Business Update
Delivering on broad 2022 second-generation vaccine development program with expansion into modified mRNA technology in collaboration with GSK; new candidates in COVID-19 and influenza enter clinical studies
Phase 1 initiated for modified [ … ]
Thu, 18.08.2022
CureVac
CureVac Announces Financial Results for the Second Quarter and First Half of 2022 and Provides Business Update
Delivering on broad 2022 second-generation vaccine development program with expansion into modified mRNA technology in collaboration with GSK; new candidates in COVID-19 and influenza enter clinical studies
Phase 1 initiated for modified [ … ]
Thu, 18.08.2022
CureVac
CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate
Phase 1 dose-escalation study to be conducted at clinical sites in the U.S., the UK, Australia, and the Philippines
Milestone demonstrates CureVac’s continued execution on comprehensive clinical program of second-generation vaccine candidates for in [ … ]
Thu, 18.08.2022
CureVac
CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate
Phase 1 dose-escalation study to be conducted at clinical sites in the U.S., the UK, Australia, and the Philippines
Milestone demonstrates CureVac’s continued execution on comprehensive clinical program of second-generation vaccine candidates for in [ … ]
Tue, 05.07.2022
CureVac
CureVac Files Patent Infringement Lawsuit in Germany Against BioNTech
TÜBINGEN, Germany/ Boston, USA – July 5, 2022 – CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”) today announced that it has moved to assert its intellectual propert [ … ]
Tue, 05.07.2022
CureVac
CureVac Files Patent Infringement Lawsuit in Germany Against BioNTech
TÜBINGEN, Germany/ Boston, USA – July 5, 2022 – CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”) today announced that it has moved to assert its intellectual propert [ … ]
Wed, 22.06.2022
CureVac
CureVac Announces Voting Results of General Meeting
TÜBINGEN, Germany / BOSTON, USA – June 22, 2022 – CureVac N.V. (Nasdaq: CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced the voting results of the Company's annual genera [ … ]